Increasing Geriatric Male Population Driving Market Growth Due to Higher Disease Prevalence and Rising Treatment Demand Is Supporting Development Across The Prostate Cancer Drugs Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Much Larger Will The Prostate Cancer Drugs Market Become By 2030 Compared To 2026?

The prostate cancer drugs market has seen strong growth in recent years. It is anticipated to increase from $19.51 billion in 2025 to $20.54 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.3%. This historical expansion can be attributed to an aging male population, increased prostate cancer screening, widespread adoption of hormone therapy, the expansion of oncology clinics, and rising cancer awareness.

The prostate cancer drugs market size is projected to experience significant expansion in the coming years. It is forecast to reach a value of **$26.15 billion in 2030, with a compound annual growth rate (CAGR) of 6.2%.** This anticipated expansion during the forecast period stems from various factors, including the increasing development of targeted and immunotherapy drugs, a rising incidence of advanced prostate cancer, greater personalization in treatment, expanding access to healthcare, and an increase in oncology spending. Important trends anticipated over this period involve the rising use of hormonal therapy in early treatment, increased adoption of targeted prostate cancer drugs, a growing focus on castration-resistant prostate cancer, the expansion of combination therapy approaches, and increased hospital-based prostate cancer care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2592&type=smp

Which Growth Drivers Are Expected To Support The Prostate Cancer Drugs Market Forward?

The expanding demographic of older men is anticipated to fuel the expansion of the prostate cancer drugs market in the future. This group encompasses males aged 65 and above, who commonly face a higher incidence of age-related health issues and necessitate specific medical care. This growth in the elderly male demographic stems from enhanced healthcare availability, reduced death rates, and extended global lifespans. A growing population of older men boosts the demand for prostate cancer drugs by increasing the pool of individuals needing hormonal therapies, immunotherapies, chemotherapy, and targeted medicines for managing the disease and improving survival rates. For example, in February 2025, the World Health Organization, an international public health body based in Switzerland, reported that global life expectancy at birth reached 73.3 years in 2024, and the number of people aged 60 and older worldwide is forecast to increase from 1.1 billion in 2023 to 1.4 billion by 2030. Consequently, the expanding older male population is propelling the growth of the prostate cancer market. The increasing occurrence of prostate cancer is anticipated to drive the expansion of the prostate cancer drugs market in the coming years. This malignancy forms in the prostate gland and necessitates prompt and effective treatment to lessen complications and enhance patient results. The surge in prostate cancer cases largely stems from an aging demographic and greater utilization of screening techniques, such as prostate-specific antigen (PSA) testing, resulting in improved detection rates. Prostate cancer medications are advantageous for treatment because they target particular alterations within prostate cancer cells that promote their growth. Their mechanism of action differs from that of chemotherapy and hormone therapy. For instance, in January 2023, the American Cancer Society, a voluntary health organization in the US committed to eradicating cancer, estimated approximately 288,300 new cases of prostate cancer and around 34,700 deaths from prostate cancer. Roughly 1 man in 8 will receive a prostate cancer diagnosis during his life. Consequently, the increasing prevalence of cancer is fueling the expansion of the prostate cancer drugs market.

Which Segment Divisions Form The Structure Of The Prostate Cancer Drugs Market?

The prostate cancer drugs market covered in this report is segmented –

1) By Type: Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer

2) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy

3) By End User: Hospitals, Clinics, Other End-Users

Subsegments:

1) By Hormone Sensitive Prostate Cancer: Early-Stage Prostate Cancer, Locally Advanced Prostate Cancer, Metastatic Prostate Cancer

2) By Hormone Refractory Prostate Cancer: Castration-Resistant Prostate Cancer (CRPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)

What Trends Are Influencing The Prostate Cancer Drugs Market?

Major entities within the prostate cancer drugs market are concentrating their efforts on launching new products and obtaining their endorsement from federal agencies to boost their revenues. The journey of drug development and subsequent approval is protracted and complex, highlighting the necessity for drug sponsors to grasp the regulatory oversight and marketing avenues required to assure reasonable safety and effectiveness. As an illustration, in June 2023, AstraZeneca PLC, a UK-based pharmaceutical company, alongside Merck & Co. Inc., a US-based pharmaceutical company, declared the United States Food and Drug Administration’s (USFDA) approval of LYNPARZA (olaparib) Plus Abiraterone and Prednisone or Prednisolone. This approval is for the treatment of adult patients diagnosed with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). An exploratory subgroup analysis from the Phase 3 PROpel trial, which underpinned this approval, revealed that LYNPARZAplus abi/pred exhibited clinically meaningful improvements in both radiographic progression-free survival (rPFS) and overall survival (OS) compared to abi/pred alone in patients with BRCAm mCRPC.

Which Organizations Are Involved In The Prostate Cancer Drugs Market?

Major companies operating in the prostate cancer drugs market are Astellas Pharma Inc., AstraZeneca PLC, Johnson & Johnson, Sanofi S.A., Bayer AG, Abbott Laboratories, Pfizer Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Tolmar Inc., AbbVie Inc., Siemens Healthineers AG, Genomic Health Inc., OPKO Health Inc., Siemens Healthcare GmbH, MDxHealth SA, Myriad Genetics Inc., Janssen Biotech Inc., Clovis Oncology Inc., Merck Sharp & Dohme Corp., Dendreon Corporation, Ferring Pharmaceuticals Inc., Ipsen Biopharmaceuticals Inc., Merck & Co. Inc., Eli Lilly and Company Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Exelixis Inc.

Access The Complete Prostate Cancer Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Which Area Represents The Largest Portion Of The Prostate Cancer Drugs Market?

North America was the largest region in the prostate cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the prostate cancer drugs market during the forecast period. The regions covered in the prostate cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Prostate Cancer Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=2592&type=smp

Browse Through More Reports Similar to the Global Prostate Cancer Drugs Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Metastatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report

Bladder Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795